AstraZeneca PLC - Cost of Goods Sold Including Depreciation and Amortization

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Cost-of-Goods-Sold-Including-Depreciation-and-Amortization" stands at 13.48 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2024.

AstraZeneca PLC's third quarter result of 2.86 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents a decrease of -22.33 percent compared to it's second quarter result.

Also, AstraZeneca PLC's third quarter result of 2.86 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents a decrease of -29.13 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 13.48 Billion USD for the item "Cost of Goods Sold Including Depreciation and Amortization" represents a decrease of -8.03 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -1.33 percent compared to the value the year prior.
The 1 year change in percent is -1.33.
The 3 year change in percent is -24.49.
The 5 year change in percent is 109.31.
The 10 year change in percent is 167.24.

The Serie's long term average value is 8.11 Billion United States Dollars. It's latest available value, on 09/30/2025, is 66.15 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 06/30/2017, to it's latest available value, on 09/30/2025, is +262.88%.
The Serie's change in percent from it's maximum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is -28.55%.